{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:18:09Z","timestamp":1792671489829,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["CHRPJ-508393-2017"],"award-info":[{"award-number":["CHRPJ-508393-2017"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CPG-151963"],"award-info":[{"award-number":["CPG-151963"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jconrel.2020.12.050","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T11:55:53Z","timestamp":1609156553000},"page":"738-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["In situ-gelling starch nanoparticle (SNP)\/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide"],"prefix":"10.1016","volume":"330","author":[{"given":"Michael J.","family":"Majcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Babar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lofts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlyn","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahed","family":"Abu-Hijleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels M.B.","family":"Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Hoare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jconrel.2020.12.050_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0116820","article-title":"The global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 2010","volume":"10","author":"Whiteford","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.12.050_bb0010","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/NDT.S49263","article-title":"Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care","volume":"9","author":"Tong Chien","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.jconrel.2020.12.050_bb0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2020.12.050_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0306-4530(02)00110-5","article-title":"Efficacy of newer generation antipsychotics in the treatment of schizophrenia","volume":"28","author":"Tandon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jconrel.2020.12.050_bb0025","series-title":"Treating Schizophrenia: A Quick Reference Guide","author":"McIntyre","year":"2007"},{"issue":"5","key":"10.1016\/j.jconrel.2020.12.050_bb0030","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1192\/bjp.169.5.580","article-title":"The course of schizophrenia over 13 years: a report from the International Study on Schizophrenia (ISoS) coordinated by the World Health Organization","volume":"169","author":"Mason","year":"1996","journal-title":"Br. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.jconrel.2020.12.050_bb0035","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1742-1241.2009.02191.x","article-title":"Worldwide-schizophrenia outpatient health outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients","volume":"63","author":"Karagianis","year":"2009","journal-title":"Int. J. Clin. Pract."},{"issue":"4","key":"10.1016\/j.jconrel.2020.12.050_bb0040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/2045125312474019","article-title":"Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review","volume":"3","author":"Higashi","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0045","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: an efficient and non-invasive route for systemic administration - focus on opioids","volume":"134","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2020.12.050_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-08294-y","article-title":"Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson\u2019s disease","volume":"10","author":"van Kessel","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2020.12.050_bb0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.schres.2016.11.027","article-title":"Intranasal delivery of antipsychotic drugs","volume":"184","author":"Katare","year":"2017","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.jconrel.2020.12.050_bb0060","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0169-409X(01)00167-3","article-title":"Microparticles for intranasal immunization","volume":"51","author":"Vajdy","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2020.12.050_bb0065","first-page":"110","article-title":"Nasal drug delivery: an overview","volume":"3","author":"Ghori","year":"2015","journal-title":"Am. J. Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2020.12.050_bb0070","unstructured":"Rene Holm, L. B. United States Patent, US 9,610,287 B2, 2014."},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0075","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0080","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.114.213819","article-title":"Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2020.12.050_bb0085","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bbr.2017.02.036","article-title":"RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia","volume":"332","author":"Rajagopal","year":"2017","journal-title":"Behav. Brain Res."},{"issue":"6","key":"10.1016\/j.jconrel.2020.12.050_bb0090","first-page":"621","article-title":"Bitopertin: the good news and bad news","volume":"71","author":"Goff","year":"2014","journal-title":"JAMA Psych."},{"issue":"4","key":"10.1016\/j.jconrel.2020.12.050_bb0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/14728214.2014.958148","article-title":"Emerging drugs for schizophrenia: an update","volume":"19","author":"K\u00f6ster","year":"2014","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"December","key":"10.1016\/j.jconrel.2020.12.050_bb0100","article-title":"The dopamine allosteric agent, PAOPA, demonstrates therapeutic potential in the phencyclidine NMDA pre-clinical rat model of schizophrenia","volume":"12","author":"Daya","year":"2018","journal-title":"Front. Behav. Neurosci."},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.euroneuro.2012.04.010","article-title":"PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia","volume":"23","author":"Beyaert","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.jconrel.2020.12.050_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0070736","article-title":"Effects of the dopamine D2 allosteric modulator, PAOPA, on the expression of GRK2, Arrestin-3, ERK1\/2, and on receptor internalization","volume":"8","author":"Basu","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jconrel.2020.12.050_bb0115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.schres.2010.09.025","article-title":"PAOPA, a potent analogue of pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in Schi","volume":"125","author":"Dyck","year":"2011","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2020.12.050_bb0120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejpb.2014.02.007","article-title":"Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)-block-Poly(D,L)-lactic-co-glycolic acid (PEG-PLGA) nanoparticles for the treatment of schizophrenia","volume":"87","author":"Piazza","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.12.050_bb0125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.peptides.2015.01.004","article-title":"Change in expression of vesicular protein synapsin II by chronic treatment with D2 allosteric modulator PAOPA","volume":"66","author":"Basu","year":"2015","journal-title":"Peptides"},{"key":"10.1016\/j.jconrel.2020.12.050_bb0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.peptides.2013.02.004","article-title":"Preclinical pharmacokinetic and toxicological evaluation of MIF-1 peptidomimetic, PAOPA: examining the pharmacology of a selective dopamine D2 receptor allosteric modulator for the treatment of schizophrenia","volume":"42","author":"Tan","year":"2013","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/j.jconrel.2020.12.050_bb0135","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1208\/s12248-015-9719-7","article-title":"Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases","volume":"17","author":"Meredith","year":"2015","journal-title":"AAPS J."},{"issue":"10","key":"10.1016\/j.jconrel.2020.12.050_bb0140","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.bmc.2017.11.001","article-title":"Nose-to-brain peptide delivery \u2013 the potential of nanotechnology","volume":"26","author":"Samaridou","year":"2018","journal-title":"Bioorgan. Med. Chem."},{"issue":"April","key":"10.1016\/j.jconrel.2020.12.050_bb0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","article-title":"Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs","volume":"281","author":"Agrawal","year":"2018","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2020.12.050_bb0150","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/17425247.2020.1762563","article-title":"Nose-to-brain delivery of antipsychotics using nanotechnology: a review","volume":"17","author":"Tan","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2020.12.050_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics10010034","article-title":"Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting","volume":"10","author":"Sonvico","year":"2018","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.jconrel.2020.12.050_bb0160","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.jconrel.2020.12.050_bb0165","first-page":"1070","article-title":"Effect of absorption enhancers on nasal delivery of basic fibroblast growth factor","volume":"5","author":"Chengcheng","year":"2011","journal-title":"African J. Pharm. Pharmacol."},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0170","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1021\/acs.molpharmaceut.5b00854","article-title":"Visualization and quantitative assessment of the brain distribution of insulin through nose-to-brain delivery based on the cell-penetrating peptide noncovalent strategy","volume":"13","author":"Kamei","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.12.050_bb0175","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.expneurol.2013.01.015","article-title":"Intranasal delivery of cell-penetrating anti-NF-\u039aB peptides (Tat-NBD) alleviates infection-sensitized hypoxic-ischemic brain injury","volume":"247","author":"Yang","year":"2013","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.jconrel.2020.12.050_bb0180","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.peptides.2012.05.021","article-title":"Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins","volume":"36","author":"Nonaka","year":"2012","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.jconrel.2020.12.050_bb0185","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jconrel.2006.12.014","article-title":"Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterisation studies","volume":"118","author":"Charlton","year":"2007","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2020.12.050_bb0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5185\/amlett.2010.3108","article-title":"Carboxymethyl chitosan and its applications","volume":"1","author":"Mourya","year":"2010","journal-title":"Adv. Mater. Lett."},{"issue":"2","key":"10.1016\/j.jconrel.2020.12.050_bb0195","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ejpb.2007.12.001","article-title":"Effective Insulin Delivery Using Starch Nanoparticles as a Potential Trans-nasal Mucoadhesive Carrier","volume":"69","author":"Kumar","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1-2","key":"10.1016\/j.jconrel.2020.12.050_bb0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2003.11.028","article-title":"Intranasal Administration of Melatonin Starch Microspheres","volume":"272","author":"Mao","year":"2004","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.jconrel.2020.12.050_bb0205","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1021\/acssuschemeng.7b02727","article-title":"Characterization and drug delivery properties of OSA starch-based nanoparticles prepared in [C3OHmim]ac-in-oil microemulsions system","volume":"5","author":"Qi","year":"2017","journal-title":"ACS Sustain. Chem. Eng."},{"key":"10.1016\/j.jconrel.2020.12.050_bb0210","series-title":"Drug Delivery Composition for the Nasal Administration of Antiviral Agents. US 2001\/0053359 A1","author":"Watts","year":"2001"},{"issue":"8","key":"10.1016\/j.jconrel.2020.12.050_bb0215","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3109\/02652040802685043","article-title":"Respiratory delivery of theophylline by size-targeted starch microspheres for treatment of asthma","volume":"26","author":"Momeni","year":"2009","journal-title":"J. Microencapsul."},{"issue":"2","key":"10.1016\/j.jconrel.2020.12.050_bb0220","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nantod.2014.04.008","article-title":"Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects","volume":"9","author":"Barua","year":"2014","journal-title":"Nano Today"},{"issue":"2","key":"10.1016\/j.jconrel.2020.12.050_bb0225","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.polymer.2010.11.058","article-title":"Insight on the periodate oxidation of dextran and its structural vicissitudes","volume":"52","author":"Maia","year":"2011","journal-title":"Polymer"},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0230","first-page":"173","article-title":"Starch paste clarity","volume":"66","author":"Criag","year":"1989","journal-title":"Cereal Chem."},{"issue":"4","key":"10.1016\/j.jconrel.2020.12.050_bb0235","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF03218520","article-title":"Preparation of highly cross-linked, monodisperse poly(methyl methacrylate) microspheres by dispersion polymerization; part II. Semi-continuous processes","volume":"16","author":"Lee","year":"2008","journal-title":"Macromol. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2020.12.050_bb0240","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/156720112803529828","article-title":"Anatomical and histological factors affecting intranasal drug and vaccine delivery","volume":"9","author":"Gizurarson","year":"2012","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.12.050_bb0245","first-page":"171","article-title":"Comparative anatomy, physiology, and function of the upper respiratory tract","volume":"85","author":"Reznik","year":"1990","journal-title":"Environ. Health Perspect."},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0250","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1152\/japplphysiol.90376.2008","article-title":"Creation of a standardized geometry of the human nasal cavity","volume":"106","author":"Liu","year":"2009","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.jconrel.2020.12.050_bb0255","series-title":"Injectable Interpenetrating Network Hydrogels for Biomedical Applications","author":"Gilbert","year":"2017"},{"issue":"1","key":"10.1016\/j.jconrel.2020.12.050_bb0260","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2273.1999.00223.x","article-title":"Nasal PH measurement: a reliable and repeatable parameter","volume":"24","author":"England","year":"1999","journal-title":"Clin. Otolaryngol. Allied Sci."},{"key":"10.1016\/j.jconrel.2020.12.050_bb0265","series-title":"Animal Models of Schizophrenia. Schizophr","first-page":"462","author":"Lipska","year":"2011"},{"key":"10.1016\/j.jconrel.2020.12.050_bb0270","first-page":"689","article-title":"Animal models relevant to schizophrenia","author":"Moghaddam","year":"2002","journal-title":"Neuropsychopharmacol. Fifth Gener. Prog."},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0275","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0165-0270(80)90012-6","article-title":"The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs","volume":"2","author":"File","year":"1980","journal-title":"J. Neurosci. Methods"},{"issue":"1","key":"10.1016\/j.jconrel.2020.12.050_bb0280","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0893-133X(97)00200-5","article-title":"Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats","volume":"19","author":"Sams-Dodd","year":"1998","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0285","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.carbpol.2009.09.019","article-title":"UV induced cross-linking of starch modified with glycidyl methacrylate","volume":"79","author":"Hedin","year":"2010","journal-title":"Carbohydr. Polym."},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0290","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/01926230600713475","article-title":"The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium","volume":"34","author":"Harkema","year":"2006","journal-title":"Toxicol. Pathol."},{"issue":"3 part 2","key":"10.1016\/j.jconrel.2020.12.050_bb0295","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/0091-6749(92)90162-U","article-title":"Human nasal host defense and sinusitis","volume":"90","author":"Kaliner","year":"1992","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2020.12.050_bb0300","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1164\/ajrccm.160.2.9805117","article-title":"Effect of biochemical components on rheologic properties of nasal mucus in chronic sinusitis","volume":"160","author":"Majima","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2020.12.050_bb0305","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8676343","article-title":"In vitro biocompatibility evaluation of nine dermal fillers on L929 cell line","volume":"2020","author":"Cannella","year":"2020","journal-title":"Biomed. Res. Int."},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0310","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MLG.0b013e31802e927b","article-title":"Hypoxia stimulates inflammatory and fibrotic responses from nasal-polyp derived fibroblasts","volume":"117","author":"Early","year":"2007","journal-title":"Laryngoscope"},{"issue":"4","key":"10.1016\/j.jconrel.2020.12.050_bb0315","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1600-0668.2003.00155.x","article-title":"Significance of humidity and temperature on skin and upper airway symptoms","volume":"13","author":"Reinikainen","year":"2003","journal-title":"Indoor Air"},{"issue":"5","key":"10.1016\/j.jconrel.2020.12.050_bb0320","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.pnpbp.2005.03.004","article-title":"(+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia","volume":"29","author":"Rung","year":"2005","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.jconrel.2020.12.050_bb0325","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1742-7843.2004.pto950507.x","article-title":"(+) MK-801 and phencyclidine induced neurotoxicity do not cause enduring behaviours resembling the positive and negative symptoms of schizophrenia in the rat","volume":"95","author":"Sams-Dodd","year":"2004","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0330","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.jconrel.2020.12.050_bb0335","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.biopsych.2006.05.008","article-title":"Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?","volume":"59","author":"Powell","year":"2006","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.jconrel.2020.12.050_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/polym10030252","article-title":"Starch-chitosan polyplexes: a versatile carrier system for anti-infectives and gene delivery","volume":"10","author":"Yasar","year":"2018","journal-title":"Polymers"},{"key":"10.1016\/j.jconrel.2020.12.050_bb0345","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.foodchem.2016.10.138","article-title":"Molecular structure, functionality and applications of oxidized starches: a review","volume":"221","author":"Vanier","year":"2017","journal-title":"Food Chem."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920307744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920307744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:07:42Z","timestamp":1778674062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920307744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":69,"alternative-id":["S0168365920307744"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.050","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In situ-gelling starch nanoparticle (SNP)\/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}